These ligand–biomaterial complexes are promising for diagnostic and therapeutic purposes, e.g., for the selective recognition of Gal-3 both on the cell surface and in blood serum, and for the treatment of various disorders, particularly cancer [13]. Here, LGALS3 is linked to cancer.